Online inquiry

IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8068MR)

This product GTTS-WQ8068MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD33 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001082618.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 945
UniProt ID P20138
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ8068MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9705MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ5846MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ12163MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ13658MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ9991MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ12867MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ1319MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ11172MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI0562
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW